Edesa Biotech Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-17.3%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$1.99next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly10MTarget: Sufficient capital to fund operations through clinical milestones
Net Loss Quarterly-4.2MTarget: Minimize cash burn while advancing clinical programs
Research and Development Expenses Quarterly2.8MTarget: Efficient allocation of capital to EB06 and paridiprubart
Watch Items
- Initiation of Phase 2 clinical trial for EB06 in vitiligoTrigger: Canadian investigational site initiation in mid-2026Action: Monitor patient enrollment rates and regulatory feedback from the FDA
- Regulatory discussions for paridiprubart (EB05) in ARDSTrigger: Meeting with regulatory authorities to discuss Phase 3 data and next stepsAction: Assess potential pathways for expedited approval or emergency use authorization
- Going concern and capital runwayTrigger: Cash burn rate exceeding available capital reservesAction: Evaluate additional financing options, including equity sales, government grants, or strategic partnerships
Research as of 20 Jun 2026